Evidence map›Paper›PMID 38909338›Full record

ArticleInfectious diseases and therapy2024

Perceived Risk for Severe COVID-19 and Oral Antiviral Use Among Antiviral-Eligible US Adults.

Kate Penrose, Avantika Srivastava, Yanhan Shen, McKaylee M Robertson, Sarah G Kulkarni, Kristen E Allen, Thomas M Porter, Laura Puzniak, John M McLaughlin, Denis Nash

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious diseases and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kate PenroseInstitute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), 55 W. 125 Street, 6 Floor, New York, NY, 10027, USA. kate.penrose@sph.cuny.edu.ORCID http://orcid.org/0000-0002-7808-7439
Avantika SrivastavaInstitute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), 55 W. 125 Street, 6 Floor, New York, NY, 10027, USA.
Yanhan ShenInstitute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), 55 W. 125 Street, 6 Floor, New York, NY, 10027, USA.
McKaylee M RobertsonInstitute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), 55 W. 125 Street, 6 Floor, New York, NY, 10027, USA.
Sarah G KulkarniInstitute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), 55 W. 125 Street, 6 Floor, New York, NY, 10027, USA.
Kristen E AllenPfizer Inc., New York, NY, USA.
Thomas M PorterPfizer Inc., New York, NY, USA.
Laura PuzniakPfizer Inc., New York, NY, USA.
John M McLaughlinPfizer Inc., New York, NY, USA.
Denis NashInstitute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), 55 W. 125 Street, 6 Floor, New York, NY, 10027, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOral antiviral medications are important tools for preventing severe COVID-19 outcomes. However, their uptake remains low for reasons that are not entirely understood. Our study aimed to assess the association between perceived risk for severe COVID-19 outcomes and oral antiviral use among those who were eligible for treatment based on Centers for Disease Control and Prevention (CDC) guidelines.

methodsWe surveyed 4034 non-institutionalized US adults in April 2023, and report findings from 934 antiviral-eligible participants with at least one confirmed SARS-CoV-2 infection since December 1, 2021 and no current long COVID symptoms. Survey weights were used to yield nationally representative estimates. The primary exposure of interest was whether participants perceived themselves to be "at high risk for severe COVID-19." The primary outcome was use of a COVID-19 oral antiviral within 5 days of suspected SARS-CoV-2 infection.

resultsOnly 18.5% of antiviral-eligible adults considered themselves to be at high risk for severe COVID-19 and 16.8% and 15.9% took oral antivirals at any time or within 5 days of SARS-CoV-2 infection, respectively. In contrast, 79.8% were aware of antiviral treatments for COVID-19. Perceived high-risk status was associated with being more likely to be aware (adjusted prevalence ratio [aPR]: 1.11 [95% confidence interval (CI) 1.03-1.20]), to be prescribed (aPR 1.47 [95% CI 1.08-2.01]), and to take oral antivirals at any time (aPR 1.61 [95% CI 1.16-2.24]) or within 5 days of infection (aPR 1.72 [95% CI 1.23-2.40]).

conclusionsDespite widespread awareness of the availability of COVID-19 oral antivirals, more than 80% of eligible US adults did not receive them. Our findings suggest that differences between perceived and actual risk for severe COVID-19 (based on current CDC guidelines) may partially explain this low uptake.

Indexed as

COVID-19Oral antiviral usePerceived risk

Identifiers

PMID38909338
PMCPMC11266331

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.